IncellDx has signed a supply agreement with Accuri Cytometers that combines new patented technology from IncellDx with the capabilities available from the Accuri C6 Flow Cytometer technology.

IncellDx claimed that the HPV OncoTect E6, E7 mRNA test provides quantification of the over expression of E6/E7 mRNA in each cell, as well as the total proportion of cells that are over expressing.

IncellDx said that the HPV OncoTect test can be performed directly on routine liquid-based cytology samples and provides results in about 3.5 hours. An automation upgrade is also available that allows 96 samples to be performed in just two hours. The HPV OncoTect test is CE marked and is available in Europe, South America, and Southeast Asia.

Additionally, C6 flow cytometer also performs additional tests from the IncellDx product line, including the Hivtropism Probe and the HCVVR Viral Reservoirs Probe. These probes are currently available as Research Use Only (RUO) products and are being used in Phase II-III clinical trials of new therapeutics to determine patient response.

Bruce Patterson, CEO of IncellDx, said: “The robust, bench-top flow cytometer system has performed well when combined with reagents from the HPV OncoTectTM E6, E7 mRNA Kit.

“With this agreement IncellDx is expected to have an automated solution for cervical cancer screening with the potential to be widely disseminated in the market.”